Origin and value of the G-Technology

G-Technology was developed by the Industrial Technology Research Institute (ITRI) in Hsin-Chu, Taiwan R.O.C. In 2005, the ITRI drug delivery department of Dr. Maggie Lu filed a series of patents describing glutathione-mediated drug delivery to the brain. Due to its pioneering work in the blood-brain barrier field, 2-BBB recognized the superior translational value of the technology. The well-known components of the formulation and the endogenous ligand would offer significant risk, time and cost reduction in clinical trials and manufacturing. In a field where clinical technologies are sparce, the G-Technology was most suitable to 2-BBB’s mission in transforming the lives of patients affected with brain diseases faster and more successful. In 2008, 2-BBB obtained the exclusive worldwide rights to commercialize these patents for the targeted delivery of drugs to the brain. 

Combining drugs with well-known, safe components to develop a novel medicine

2-BBB’s G-Technology enables sustained delivery of systemically administered therapeutics while safely enhancing their brain delivery. It carries therapeutics in small vesicles, so-called liposomes, thereby protecting the body from side effects caused by peak drug concentrations in the blood. 

Polyethylene glycol (PEG) is attached to the liposomes to ensure a prolonged circulation time in the blood stream. Glutathione is conjugated to the PEG molecules to safely enhance delivery of the therapeutics across the blood-brain barrier.